Please upgrade your browser.
For months now, the Food and Drug Administration has been trying novel ways of encouraging drug makers to develop drugs for rare diseases.
We have received many positive comments about the exhibits attendees not only appreciated the variety of topics but noted how nice it was to talk with each of you you were all so welcoming and responded so well to the various questions and concerns of the survivors. --Linda L. Rohret, M.A., R.H.Ed
Semafore Pharmaceuticals Presents New Clinical Data on Novel Prodrug Dual PI3K-mTOR Inhibitor in B-Cell Malignancies and Solid Tumors
Semafore Pharmaceuticals today announced the presentation of preliminary clinical data demonstrating that SF1126 has clinical activity in chronic lymphocytic leukemia (CLL). SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). The results were presented at Cambridge Healthtech Institute's 8th Annual Next-Gen Kinase Inhibitors Oncology & Beyond Conference being held June 21-23, 2010, in Cambridge, Massachusetts.
Cambridge scientists have discovered a new class of cancer gene, occupying the central control position of gene activity and acting to keep cells from turning cancerous.
When things go bump in the night, Sgt. Scott Paske has been one of the first people on the scene to help Livingston residents. Now the Polk County community is reaching out to help the Livingston Police Officer battle kidney cancer.
Single Institutional Experience With Nephron-sparing Surgery For Pathologic Stage T3bNxM0 Renal Cell Carcinoma Confined To The Renal Vein
Our study of nephron-sparing surgery in renal cell carcinoma (RCC) invading the segmental branches of the renal vein is consistent with the trend towards increased utilization of "partial nephrectomy" during surgical management of RCC.
Ten years ago, the board of Bickelhaupt Arboretum asked Francie Hill if she would come back to her hometown of Clinton, Iowa, and help run the 14-acre outdoor plant museum her parents had founded.
Kidney Cancer Association CEO Bill Bro has accepted an invitation from the National Cancer Institute (NCI) to join the currently forming Renal Cancer Task Force (RCTF). The RCTF is a part of NCI's Genitourinary Steering Committee (GUSC). The GUSC and other organ system based steering committees were formed as part of NCI's effort to enhance its clinical trials enterprise.
XL184 is an investigational oral inhibitor of MET, VEGFR2, and RET that produces antiangiogenic, antiproliferative, and antiinvasive effects in preclinical tumor models. MET is mutationally activated in some tumor types, such as hereditary and sporadic papillary renal cell carcinoma and some head and neck cancers.
AVEO Pharmaceuticals Granted Patents For Diagnostic Tests To Identify Patient Populations Likely To Respond To Tivozanib Treatment
These patents cover two different diagnostic tests for identifying human patients likely to respond to treatment with tivozanib, AVEO's highly potent and selective inhibitor of VEGF receptors 1, 2 and 3, which is currently being evaluated in a global Phase 3 clinical trial, TIVO-1, in patients with renal cell cancer (RCC).
|Powered by NeonCRM|